Increase in Papillary Thyroid Cancer Incidence is Accompanied by Changes in the Frequency of the BRAFV600E Mutation: A Single-Institution Study

Thyroid

Volumn 26, Issue 4, 2016, Pages 543-551

  Kowalska, Aldona ^a   Walczyk, Agnieszka ^a   Kowalik, Artur ^a   Pałyga, Iwona ^a   Trybek, Tomasz ^a   Kopczyński, Janusz ^a   Kajor, Maciej ^b   Chrapek, Magdalena ^c   Piȩciak, Liliana ^a   Chłopek, Małgorzata ^a   Gózdz, Stanisław ^a,c   Kamiński, Grzegorz ^d  

^a Holycross Cancer Centre   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c JAN KOCHANOWSKI UNIVERSITY   (Poland)

^d MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BRAF GENE; CANCER DIAGNOSIS; CANCER INCIDENCE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DISTANT METASTASIS; DNA ISOLATION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; ONCOGENE; POLAND; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; THYROID PAPILLARY CARCINOMA; TREND STUDY; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; CARCINOMA; CHEMISTRY; DNA MUTATIONAL ANALYSIS; GENETICS; INCIDENCE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDY; THYROID NEOPLASMS; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; INCIDENCE; IODINE; MALE; MIDDLE AGED; MUTATION; POLAND; POLYMERASE CHAIN REACTION; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 84963818691     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0352     Document Type: Article

References (49)

1. Morris LG, Sikora AG, Tosteson TD, Davies L 2013 The increasing incidence of thyroid cancer: The influence of access to care. Thyroid 23:885-891.
2. Wojciechowska U, Didkowska J. Cancer incidence and mortality in Poland. Polish National Cancer Registry, Maria Sklodowska-Curie Memorial Cancer Centre Institute of Oncology. Available at: http://onkologia.org.pl/raporty/(accessed April 29, 2015).
3. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, Negri E 2015 Thyroid cancer mortality and incidence: A global overview. Int J Cancer 136: 2187-2195.
4. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690-1694.
5. Morris LG, Sikora AG, Myssiorek D, DeLacure MD 2008 The basis of racial differences in the incidence of thyroid cancer. Ann Surg Oncol 15:1169-1176.
6. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM 2007 Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: A morphological and epidemiological study. Endocr Pathol 18:1-7.
7. Sipos JA, Mazzaferri EL 2010 Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22:395-404.
8. Roman S, Lin R, Sosa JA 2006 Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142.
9. Sobrinho-Simões M, Eloy C, Magalhães J, Lobo C, Amaro T 2011 Follicular thyroid carcinoma. Mod Pathol 24: S10-18.
10. Kowalska A, Sygut J, Suszniak J, Walczyk A, Payga I, Gąsior-Perczak D, Gadawska-Juszczyk K, Szyska-Skrobot D, Trybek T, Hurej S, Mȩzyk R, Stanisaw Góźdź S 2013 Variation of the epidemiological structure of thyroid cancer between year 2000 and 2012. Thyroid Res 6:A30.
11. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762.
12. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M 2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28:305-308.
13. Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS, Hwang TS 2009 Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 19:137-141.
14. Gandolfi G, Sancisi V, Piana S, Ciarrocchi A 2015 Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma. Int J Cancer 137:1001-1011.
15. Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A 2014 BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg 38:679-687.
16. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D,Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R 2012 Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 97:E1758-1765.
17. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ, Nikiforov YE 2014 The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 99:E276-285.
18. Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, Kebebew E 2011 Higher rate of BRAF mutation in papillary thyroid cancer over time: A single-institution study. Cancer 117:4390-4395.
19. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M 2009 Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94:1612-1617.
20. Williams ED, Doniach I, Bjarnason O, Michie W 1977 Thyroid cancer in an iodide rich area: A histopathological study. Cancer 39:215-222.
21. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, Regalbuto C, Vigneri R 1992 Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 93: 363-369.
22. Zarządzenie Ministra Zdrowia i Opieki Spo1ecznej z dnia 24 lipca 1996r. 1996 Monitor Polski 48:462.
23. Szybinski Z, Delange F, Lewinski A, Podoba J, Rybakowa M, Wasik R, Szewczyk L, Huszno B, Gokowski F, Przybylik-Mazurek E, Karbownik M, Zak T, Pantoflinski J, Trofimiuk M, Kinalska I 2001A programme of iodine supplementation using only iodised household salt is efficient-The case of Poland. Eur J Endocrinol 144:331-337.
24. Andersson M, de Benoist B, Darnton-Hill I, Delange F (eds) 2007 Iodine Deficiency in Europe: A Continuing Public Health Problem. World Health Organization, Geneva, Switzerland.
25. Szybiński Z, Zarnecki A 1993 Prevalence of goiter, iodine deficiency and iodine prophylaxis in Poland. Endokrynol Pol 44:373-388.
26. Szybiński Z 2012 Work of the Polish Council for Control of Iodine Deficiency Disorders, and the model of iodine prophylaxis in Poland. Endokrynol Pol 63:156-160.
27. DeLellis RA, Lloyd R, Heitz PU (eds) 2004 Tumours of Endocrine Organs, Pathology and Genetics, World Health Organization Classification of Tumours. International Agency for Research on Cancer (IARC) Press, Lyon, France.
28. Kakundo K, Bai Y, Liu Z, Ozaki T 2012 Encapsulated papillary thyroid carcinoma, follicular variant: A misnomer. Pathol Int 62:155-160.
29. Sobin LH, Gospodarowicz M, Wittekind C (eds) 2010 International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. Seventh edition. Wiley-Blackwell Publishing, Oxford.
30. Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypio rkiewicz E, Chodurska R, Piȩciak L, Góźdź S 2014 The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf) 80:899-904.
31. Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Goąbek A, Coates T, Kopczyński J, Góźdź S, Miettinen M 2014 Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imnunohistochemical approach. Am J Surg Pathol 38:1235-1241.
32. Kang SH, Pyo JY, Yang SW, Hong SW 2013 Detection of BRAFV600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and realtime PCR. Am J Clin Pathol 139:759-764.
33. Huang T, Zhuge J, Zhang WW 2013 Sensitive detection of BRAFV600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res 1:3.
34. Smyth P, Finn S, Cahill S, O'Regan E, Flavin R, O'Leary JJ, Sheils O 2005 ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int J Surg Pathol 13:1-8.
35. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, Drozdovitch V, Maceika E, Zvonova I, Vlassov O, Bouville A, Goulko G, Hoshi M, Abrosimov A, Anoshko J, Astakhova L, Chekin S, Demidchik E, Galanti R, Ito M, Korobova E, Lushnikov E, Maksioutov M, Masyakin V, Nerovnia A, Parshin V, Parshkov E, Piliptsevich N, Pinchera A, Polyakov S, Shabeka N, Suonio E, Tenet V, Tsyb A, Yamashita S, Williams D 2005 Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97:724-732.
36. Kinalska I, Zarzycki W, Zonenberg A, Rybaczuk M, Zimnicki P, Hoowaczyk H, Gosiewska A, Kulikowski M, Dzierzanowski E, Modzelewski A 1991 Results of studies on the effect of radiologic contamination after the Czernobyl catastrophe and prophylactic iodine on thyroid morphology and function of inhabitants of North-East Poland. Endokrynol Pol 42:215-234.
37. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379.
38. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517-524.
39. Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D 2014 The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Biomed Pharmacother 68:413-417.
40. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-471.
41. Karbownik-Lewińska M, Kokoszko-Bilska A 2012 Oxidative damage to macromolecules in the thyroid-experimental evidence. Thyroid Res 5:25.
42. Poncin S, Gérard AC, Boucquey M, Senou M, Calderon PB, Knoops B, Lengelé B, Many MC, Colin IM 2008 Oxidative stress in the thyroid gland: from harmlessness to hazard depending on the iodine content. Endocrinology 149:424-433.
43. Poncin S, Van Eeckoudt S, Humblet K, Colin IM, Gérard AC 2010 Oxidative stress: A required condition for thyroid cell proliferation. Am J Pathol 176:1355-1363.
44. Lewiński A, Szybiński Z, Bandurska-Stankiewicz E, Grzywa M, Karwowska A, Kinalska I, Kowalska A, Makarewicz J, Nauman J, Sowińska-Klencka D, Sowiński J, Syrenicz A, Zonenberg A, Huszno B, Klencki M 2003 Iodine-induced hyperthyroidism-an epidemiological survey several years after institution of iodine prophylaxis in Poland. J Endocrinol Invest 26:57-62.
45. Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, Lewiński A 2007 Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett 28:351-359.
46. Czarniecka A, Rusinek D, Stobiecka E, Krajewska J, Kowal M, Kropińska A, Zebracka J, KowalskaM,Woch J, Maciejewski A, Handkiewicz-Junak D 2010 Occurrence of BRAF mutations in a Polish cohort of PTC patients-preliminary results. Endokrynol Pol 61:462-466.
47. Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, Maciejewski A, Zebracka-Gala J, Lange D, Oczko-Wojciechowska M, Handkiewicz-Junak D, Jarzab B 2015 The risk of relapse in papillary thyroid cancer (PTC) in the context of BRAFV600E mutation status and other prognostic factors. PLoS One; doi: 10.1371/journal. pone.0132821.
48. Morris LG, Myssiorek D 2010 Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: A population-based analysis. Am J Surg 200:454-461.
49. Sarne DH 2012A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab 97:3094-3096.